Regeneron Pharmaceuticals (REGN) Buildings (2010 - 2017)

Regeneron Pharmaceuticals has reported Buildings for 6 years, with the latest figure at $1.4 billion in Q4 2017.

• For the quarter ending Q4 2017, Buildings rose 12.77% year-over-year to $1.4 billion; the trailing twelve-month figure through Dec 2017 stood at $1.4 billion (up 12.77% YoY), and the FY2017 full-year result was $1.4 billion, up 12.77% from the prior year.
• Buildings for Q4 2017 stood at $1.4 billion, up from $1.3 billion in the prior quarter.
• The five-year high for Buildings was $1.4 billion in Q4 2017, with the low at $343.4 million in Q4 2013.
• Average Buildings over 5 years is $844.5 million, with a median of $760.5 million recorded in 2015.
• Year-over-year, Buildings jumped 90.61% in 2015 and gained 12.77% in 2017.
• Tracing REGN's Buildings over 5 years: stood at $343.4 million in 2013, then increased by 16.2% to $399.0 million in 2014, then jumped by 90.61% to $760.5 million in 2015, then surged by 68.08% to $1.3 billion in 2016, then gained by 12.77% to $1.4 billion in 2017.
• The last three Buildings figures came in at $1.4 billion (Q4 2017), $1.3 billion (Q4 2016), and $760.5 million (Q4 2015), per Business Quant data.

Peer Comparison